Metabolic Research
Studied for its interaction with pathways governing energy expenditure and glucose regulation.
Overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist studied for its combined engagement of two incretin pathways implicated in glucose and energy regulation.
Suria's Tirzepatide is synthesized to high purity and independently verified prior to release, giving researchers a consistent, well-documented starting point for dual-agonist pathway studies.
Research Use Only. Not for human or veterinary use.
Specifications
Third-Party Testing
Available third-party analytical documentation for Tirzepatide can be reviewed for applicable batches through Suria's Batch Documentation system. We believe documentation should be held to the same standard as the research it supports.
Certificates of Analysis will be available at time of launch.
Research Highlights
Studied for its interaction with pathways governing energy expenditure and glucose regulation.
A frequent focus of body-composition and weight-related research models.
Among the more closely followed compounds in current metabolic research literature.
Consistent, well-documented starting material for pathway and dosing-response studies.
Storage
Store at −20°C, protected from light and moisture, until ready for reconstitution.
Store at 2–8°C and use within the recommended window for your protocol.
Avoid repeated freeze-thaw cycles to help preserve peptide integrity across a research protocol.
Research Use Only. Not for human consumption.
Frequently Asked Questions
Batch Documentation